Skip to content

Released Aug 13, 2020, after the close

10-Q filed Aug 13, 2020, 44 days after period end · 0001390478-20-000026

Q2 2020 · 10-Q
Revenue$0.00no prior Q2 2019 on fileno prior Q1 2020 on file
Net Income-$4.43MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.66N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$4,267,000—
Operating Cash Flowderived-$3,381,000N/M

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$0.00———
Net Income-$4.43M-$3.13M-$6.06M-$5.91M
EPS Diluted-$0.66-$6.33-$1.26-$0.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR